If the Phase 3 trial for heart failure is as successful as we hope and expect then Mesoblast should go straight to Europe and Japan for approval. Approval in Europe would provide substantial revenue and save lives. The FDA can then watch a direct consequence of their incompetence.
If the Phase 3 trial for heart failure is as successful as we...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.030(2.60%) |
Mkt cap ! $1.364B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.17 | $15.70M | 13.22M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 35776 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 2400 | 1 |
View Market Depth
| Last trade - 15.59pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.030 ( 3.40 %) |
||||
| Open | High | Low | Volume | ||
| $1.21 | $1.21 | $1.17 | 2927691 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| MSB (ASX) Chart |